Human Vasodilatory Effect of GLP-1

Type2 Diabetes Clinical Trial

Official title:

Vasodilatory Effect of GLP-1

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03502083
• Other study ID #: 14/EE/0018
• Status: Completed
• Phase: N/A
• First received: April 3, 2018
• Last updated: April 10, 2018
• Start date: December 1, 2015
• Est. completion date: March 1, 2017

Study information

• Verified date: April 2018
• Source: Papworth Hospital NHS Foundation Trust
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Comprehensive assessment of human vasodilatory effect of GLP-1 in forearm and coronary arteries

Recruitment information / eligibility

• Status: Completed
• Enrollment: 11
• Est. completion date: March 1, 2017
• Est. primary completion date: March 1, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Waiting list for elective PCI to LAD Able to give informed consent Over 18

Exclusion Criteria:

• GLP-1 based therapy Insulin Calcium channel blockers Nicorandil Nitrates

Related Conditions & MeSH terms

• Angina, Stable
• Coronary Stenosis
• Type2 Diabetes

Intervention

Drug:
• GLP-1 (7-36)Amide
IV infusion

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Papworth Hospital NHS Foundation Trust

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in IMR (index of microcirculatory resistance) with GLP-1 compared with baseline	Change in coronary microcirculatory resistance from baseline	Change from baseline
Primary	Forearm bloodflow ratio with GLP-1	Peripheral vasodilatory response of GLP-1	Change from baseline